KPL-1161

KPL-1161 is an investigational, Fc-modified IgG2 monoclonal antibody developed by Kiniksa Pharmaceuticals. It is designed to bind interleukin-1 receptor type 1 (IL-1R1), thereby inhibiting the signaling of the pro-inflammatory cytokines interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β). The drug’s target profile includes quarterly subcutaneous dosing, aiming to provide a less frequent administration option for patients compared to existing therapies. As of mid-2025, KPL-1161 remains in preclinical/IND-enabling development with its primary focus on cardiovascular inflammatory diseases; specific indications have not been publicly disclosed[4][7][8][10].